Ausgabe 5/2016
Inhalt (16 Artikel)
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing
Masao Omata, Tatsuo Kanda, Lai Wei, Ming-Lung Yu, Wang-Long Chuang, Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Jose Sollano, Manoj Kumar, Ankur Jindal, Barjesh Chander Sharma, Saeed S. Hamid, A. Kadir Dokmeci, Mamun Al-Mahtab, Geofferey W. McCaughan, Jafri Wasim, Darrell H. G. Crawford, Jia-Horng Kao, Osamu Yokosuka, George K. K. Lau, Shiv Kumar Sarin
APASL consensus statements and recommendation on treatment of hepatitis C
Masao Omata, Tatsuo Kanda, Lai Wei, Ming-Lung Yu, Wang-Long Chuang, Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Jose Sollano, Manoj Kumar, Ankur Jindal, Barjesh Chander Sharma, Saeed S. Hamid, A. Kadir Dokmeci, Mamun-Al-Mahtab, Geofferey W. McCaughan, Jafri Wasim, Darrell H. G. Crawford, Jia-Horng Kao, Osamu Yokosuka, George K. K. Lau, Shiv Kumar Sarin
HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy
Geoffrey Dusheiko, Bo Wang, Ivana Carey
The role of bile salts in liver regeneration
Liyanne F. M. van de Laarschot, Peter L. M. Jansen, Frank G. Schaap, Steven W. M. Olde Damink
Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals
Che C. Colpitts, Thomas F. Baumert
Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review
Dinesh Jothimani, Sanjay Govil, Mohamed Rela
Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise
G. Liamis, T. D. Filippatos, A. Liontos, M. S. Elisaf
Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure
Fabien Zoulim, Jolanta Białkowska-Warzecha, Mircea Mihai Diculescu, Adrian Eugen Goldis, Renate Heyne, Tomasz Mach, Patrick Marcellin, Jörg Petersen, Krzysztof Simon, Soumaya Bendahmane, Isabelle Klauck, Wojciech Wasiak, Harry L. A. Janssen
Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients
Dong Ji, Guo-Feng Chen, Cheng Wang, Yu-Dong Wang, Qing Shao, Bing Li, Jun Zhao, Shao-Li You, Jin-Hua Hu, Jia-Liang Liu, Xiao-Xia Niu, Jing Chen, Lei Lu, Vanessa Wu, George Lau
A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
Yuko Takami, Susumu Eguchi, Masaki Tateishi, Tomoki Ryu, Kazuhiro Mikagi, Yoshiyuki Wada, Hideki Saitsu
Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis
Hong Zang, Fangfang Liu, Hongling Liu, Shaoli You, Bing Zhu, Zhihong Wan, Shaojie Xin
Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review
Gaeun Kim, Juyoung Kim, Yoo Li Lim, Moon Young Kim, Soon Koo Baik
HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes
Tien Huey Lim, Edward Gane, Chris Moyes, Barry Borman, Chris Cunningham
End-stage liver disease patients with MELD >40 have higher waitlist mortality compared to Status 1A patients
Joseph Ahn, Taft Bhuket, Sasan Mosadeghi, Catherine Frenette, Benny Liu, Robert J. Wong